Last10K.com

Aravive, Inc. (ARAV) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2019

SEC Filings

ARAV Annual Reports

    10-K Annual Report March 2022
    10-K Annual Report March 2021
  • 10-K Annual Report March 2020
  • 10-K Annual Report March 2019

Aravive, Inc.

CIK: 1513818 Ticker: ARAV

Exhibit 99.1

 

Aravive Reports Fourth Quarter and Twelve Months Ended December 31, 2019 Financial Results and Provides Recent Corporate Updates

 

 

AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020

 

Company announces clinical trial updates for clear cell renal cell carcinoma and IgA Nephropathy studies

 

Current cash runway expected to fund company into 2022

 

 

HOUSTON, March 27, 2020 (GLOBE NEWSWIRE)

-- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, announced recent corporate updates and financial results for the fourth quarter and twelve months ended December 31, 2019.

 

With the recent and rapidly evolving impact of COVID-19 on patient recruitment in clinical trials and considering patient safety and trial integrity, Aravive has decided to make certain changes to its clinical plans:

 

 

The company has decided to amend its clear cell renal cell carcinoma (ccRCC) trial to initiate treatment at 15 mg/kg or 20 mg/kg given the positive safety profile seen with the 15 mg/kg dosing cohort of the platinum resistant ovarian cancer (PROC) trial and the recent initiation of the 20 mg/kg dosing cohort in the PROC population.  While this may delay first patient dosing, the overall timelines for top line data may not be significantly impacted given the higher starting dose, assuming the COVID-19 situation does not interfere with ongoing clinical studies.

 

To reduce the risk of unnecessary exposure of patients to COVID-19 that may be caused by patients coming to health centers for their AVB-500 intravenous infusion, the company will pause new enrollment in its IgA nephropathy (IgAN) trial as this is a relatively healthy patient population with a chronic disease.

 

Aravive plans to continue enrollment in its ongoing Ph 1b dose escalation cohort at the 20 mg/kg dose in patients with PROC with the goal of targeting up to twelve patients in the trial, subject to the impact of COVID-19.

 

Based on updated clinical plans, Aravive anticipates that its cash and cash equivalents will be sufficient to fund operations into 2022.

 

 


The following information was filed by Aravive, Inc. (ARAV) on Friday, March 27, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Aravive, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aravive, Inc..

Continue

Assess how Aravive, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aravive, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Rating

Learn More
Bullish Bearish Neutral
Filter by Sentiment:
All
Positive
Negative
Filter by Category:
All
M & A
Financial
Revenue
Other
Filter by Subcategory:
All
Expense
Product
Income
Shares
Other
Inside Aravive, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Condensed Statements Of Stockholders' Equity (Parenthetical)
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Consolidated Statements Of Stockholders' Equity
Balance Sheet Components
Balance Sheet Components (Tables)
Balance Sheet Components - Accrued Liabilities (Detail)
Balance Sheet Components - Additional Information (Detail)
Balance Sheet Components - Intangible Asset, Net (Details)
Balance Sheet Components - Prepaid Expenses And Other Current Assets (Detail)
Balance Sheet Components - Property And Equipment, Net (Detail)
Commitments And Contingencies
Commitments And Contingencies - Additional Information (Detail)
Common Stock
Common Stock (Tables)
Common Stock - Additional Information (Detail)
Common Stock - Summary Of Reserved Shares Of Common Stock For Future Issuances (Detail)
Employee Benefit Plans
Employee Benefit Plans - Additional Information (Detail)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Additional Information (Detail)
Fair Value Measurements - Financial Instruments Measured At Fair Value On Recurring Basis (Detail)
Formation And Business Of The Company
Formation And Business Of The Company - Additional Information (Detail)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Detail)
Income Taxes - Reconciliation Of Amount Of Unrecognized Tax Benefits (Detail)
Income Taxes - Schedule Of Income (Loss) Before Income Taxes Attributed To Geographic Locations (Details)
Income Taxes - Significant Components Of Net Deferred Tax Assets (Detail)
Income Taxes - Summary Of Statutory Federal Tax Rate To Income Or Loss Before Taxes (Detail)
Leases
Leases (Tables)
Leases - Additional Information (Detail)
Leases - Minimum Lease Payments Under Non-Cancelable Operating Leases (Detail)
Leases - Schedule Of Future Sublease Income Term (Detail)
Leases - Summary Of Minimum Lease Payments Under Non-Cancelable Operating Leases (Detail)
Merger With Aravive Biologics, Inc - Schedule Of Estimate Purchase Price Fair Value Identifiable Tangible And Intangible Assets Acquired And Liabilities Assumed (Parenthetical) (Detail)
Merger With Aravive Biologics, Inc.
Merger With Aravive Biologics, Inc. (Tables)
Merger With Aravive Biologics, Inc. - Additional Information (Detail)
Merger With Aravive Biologics, Inc. - Schedule Of Estimate Purchase Price Fair Value Identifiable Tangible And Intangible Assets Acquired And Liabilities Assumed (Detail)
Net Loss Per Share Of Common Stock
Net Loss Per Share Of Common Stock (Tables)
Net Loss Per Share Of Common Stock - Additional Information (Detail)
Net Loss Per Share Of Common Stock - Summary Of Computation Of Basic And Diluted Net Loss Per Share (Detail)
Net Loss Per Share Of Common Stock - Summary Of Potentially Anti-Dilutive Securities Excluded From Computation Of Diluted Shares Outstanding (Detail)
Restructuring Plan
Restructuring Plan - Additional Information (Detail)
Stock Based Awards
Stock Based Awards (Tables)
Stock Based Awards - Additional Information (Detail)
Stock Based Awards - Schedule Of Estimated Stock-Based Compensation Expense (Detail)
Stock Based Awards - Stock Options Outstanding And Exercisable Under Stock Option Plans (Detail)
Stock Based Awards - Summary Of Fair Value Of Employee Stock Options (Detail)
Stock Based Awards - Summary Of Restricted Stock Activity (Detail)
Stock Based Awards - Summary Of Stock Options Activity (Detail)
Subsequent Events
Subsequent Events - Additional Information (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Ticker: ARAV
CIK: 1513818
Form Type: 10-K Annual Report
Accession Number: 0001564590-20-013390
Submitted to the SEC: Fri Mar 27 2020 8:11:44 AM EST
Accepted by the SEC: Fri Mar 27 2020
Period: Tuesday, December 31, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/arav/0001564590-20-013390.htm